title: Using nodal ratios to predict risk of regional recurrences in patients treated with breast conservation therapy with 4 or more positive lymph nodes.
abstract: Purpose. The value of nodal ratios (NRs) as a prognostic variable in breast cancer is continually being demonstrated. The purpose of this study was to use NR in patients with ≥4+ nodes to assess a correlation of NR with regional (lymph node) recurrence. Methods. Inclusion criteria was ≥8 nodes dissected with ≥4+ nodes after breast conservation therapy. Of 1060 patients treated from 1975 to 2003 who had a minimum of 8 nodes dissected, 273 were node+; 56 patients had ≥4+ involved nodes and were the focus of this study. Nodal ratios were calculated for each patient and grouped into 3 categories: high (≥70%), intermediate (40%-69%) and low (<40%). Each nodal ratio was correlated with patterns of local, regional, and distant failures and OS. Results. Outcomes for the entire cohort were BRFS-83%, NRFS-93%, DMFS-61%, and OS 63% at 10 yrs. The OS, DMFS, and NRFS correlated with N2 (4-9 nodes+) versus N3 (≥10+) status but did not correlate with BRFS, as expected. When evaluating NR, 18 pts had high NR (>70%). Only 3 patients experienced nodal recurrences, all within previously radiated supraclavicular fields. All 3 in-field regional failures occurred in the N3 group of patients with NR >70%. All were treated with a single AP field prescribed to a dose of 46 Gy at a standard depth of 3 cm. Conclusions. In this group of N2/N3 patients treated with BCT, we were able to identify patients at high risk for regional failures as those with high NR of >70% and ≥10+ nodes. While these findings need to be reproduced in larger datasets, this group of patients with NR of >70% in 4 or more positive axillary lymph nodes may benefit from meticulous targeting of regional nodes, dose escalation, and/or more intensive systemic therapies.
authors.affiliation: Department of Therapeutic Radiology, Yale University School of Medicine, 333 Cedar Street, P.O. Box 208040, New Haven, CT 06520-8040, USA.
authors.forename: William
authors.initials: W
authors.lastname: Castrucci
authors.forename: Donald
authors.initials: D
authors.lastname: Lannin
authors.forename: Bruce G
authors.initials: BG
authors.lastname: Haffty
authors.forename: Susan A
authors.initials: SA
authors.lastname: Higgins
authors.forename: Meena S
authors.initials: MS
authors.lastname: Moran
references.citation: J Clin Oncol. 2006 May 1;24(13):2028-37
references.pmid: 16648502
references.citation: Acta Oncol. 2006;45(5):564-70
references.pmid: 16864170
references.citation: Breast Cancer Res. 2004;6(6):R680-8
references.pmid: 15535850
references.citation: Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):397-403
references.pmid: 11380226
references.citation: Breast Cancer Res Treat. 2005 May;91(1):11-8
references.pmid: 15868427
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):662-6
references.pmid: 17449196
references.citation: Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):33-9
references.pmid: 16542789
references.citation: J Surg Oncol. 2004 Jul 15;87(1):4-12
references.pmid: 15221913
references.citation: Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):658-70
references.pmid: 12788171
references.citation: Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1508-13
references.pmid: 16169678
references.citation: Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):59-65
references.pmid: 17321065
references.citation: J Clin Oncol. 2001 Mar 15;19(6):1688-97
references.pmid: 11250998
references.citation: J Clin Oncol. 2005 Mar 1;23(7):1409-19
references.pmid: 15735117
references.citation: Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1320-7
references.pmid: 17049182
references.citation: Radiother Oncol. 2004 Mar;70(3):225-30
references.pmid: 15064006
references.citation: J Clin Oncol. 2006 Jun 20;24(18):2910-6
references.pmid: 16782931
references.citation: Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):755-8
references.pmid: 10837961
references.citation: Eur J Surg Oncol. 2006 Jun;32(5):498-501
references.pmid: 16580810